Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria

International Journal of Hematology

Volumn 93, Issue 4, 2011, Pages 532-541

  Sato, Takayuki ^a   Ichinohe, Tatsuo ^a   Kanda, Junya ^a,b   Yamashita, Kouhei ^a   Kondo, Tadakazu ^a   Ishikawa, Takayuki ^a   Uchiyama, Takashi ^a   Takaori Kondo, Akifumi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chronic graft versus host disease; Hematopoietic cell transplantation; NIH consensus criteria

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; RETROSPECTIVE STUDY; TREATMENT DURATION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; CONSENSUS; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NATIONAL INSTITUTES OF HEALTH (U.S.); RECURRENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; UNITED STATES; YOUNG ADULT;

EID: 79955941761     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-011-0820-0     Document Type: Article

References (37)

1. Lee S, Flowers M. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2008:134-41.
2. Atkinson K, Horowitz M, Gale R, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990;75:2459-64. (Pubitemid 20202328)
3. Higman M, Vogelsang G. Chronic graft versus host disease. Br J Haematol. 2004;125:435-54. (Pubitemid 38916189)
4. Wagner J, Flowers M, Longton G, Storb R, Schubert M, Sullivan K. The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation. Bone Marrow Transplant. 1998;22:139-46. (Pubitemid 28375652)
5. Przepiorka D, Anderlini P, Saliba R, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 2001;98:1695-700.
6. Carlens S, Ringdén O, Remberger M, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant. 1998;22:755-61. (Pubitemid 28488318)
7. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin J. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 2001;19:3685-91. (Pubitemid 32786281)
8. Mohty M, Kuentz M, Michallet M, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood. 2002;100:3128-34. (Pubitemid 35217059)
9. Randolph S, Gooley T, Warren E, Appelbaum F, Riddell S. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood. 2004;103:347-52. (Pubitemid 38029959)
10. Atsuta Y, Suzuki R, Yamamoto K, et al. Risk and prognostic factors for Japanese patients with chronic graft-versus-host disease after bone marrow transplantation. Bone Marrow Transplant. 2006;37:289-96.
11. McClune B, Weisdorf D, Pedersen T, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28:1878-87.
12. Mielcarek M, Martin P, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102:756-62. (Pubitemid 36842003)
13. Mielcarek M, Burroughs L, Leisenring W, et al. Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. Br J Haematol. 2005;129:381-91.
14. Shulman H, Sullivan K, Weiden P, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204-17. (Pubitemid 10036817)
15. Lee S, Klein J, Barrett A, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100:406-14. (Pubitemid 34761100)
16. Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215-33.
17. Atkinson K, Horowitz M, Gale R, Lee M, Rimm A, Bortin M. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1989;4:247-54.
18. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945-56.
19. Jagasia M, Giglia J, Chinratanalab W, et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant. 2007;13:1207-15. (Pubitemid 47413020)
20. Pérez-Simón J, Encinas C, Silva F, et al. Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the National Institutes Health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. Biol Blood Marrow Transplant. 2008;14:1163-71.
21. Cho B, Min C, Eom K, et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia. 2009;23:78-84.
22. Arora M, Nagaraj S, Witte J, et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant. 2009;43:149-53.
23. Kim D, Lee J, Kim S, et al. Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD. Bone Marrow Transplant. 2010;45:1174-80.
24. Flowers MED, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood. 2002; 100:415-9. (Pubitemid 34761101)
25. Stewart B, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004;104:3501-6. (Pubitemid 39564419)
26. Martin P, Weisdorf D, Przepiorka D, et al. National Institutes of Health Consensus Development Project on Criteria for clinical trials in chronic graft-versus-host disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant. 2006;12:491-505.
27. Kitawaki T, Kadowaki N, Ishikawa T, Ichinohe T, Uchiyama T. Compromised recovery of natural interferon-alpha/beta-producing cells after allogeneic hematopoietic stem cell transplantation complicated by acute graft-versus-host disease and glucocorticoid administration. Bone Marrow Transplant. 2003;32:187-94. (Pubitemid 36903443)
28. Mizumoto C, Kanda J, Ichinohe T, et al. Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning. Int J Hematol. 2009;89:538-45.
29. Kanda J, Mizumoto C, Kawabata H, et al. Clinical significance of serum hepcidin levels on early infectious complications in allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:956-62.
30. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-8.
31. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706. (Pubitemid 29126745)
32. Kim H. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res. 2007; 13:559-65. (Pubitemid 46225362)
33. Cortese G, Andersen P. Competing risks and time-dependent covariates. Biom J. 2010;52:138-58.
34. Kim DH, Sohn SK, Baek JH, et al. Time to first flare-up episode of GVHD can stratify patients according to their prognosis during clinical course of progressive- or quiescent-type chronic GVHD. Bone Marrow Transplant. 2007;40:779-84. (Pubitemid 47521538)
35. Flowers MED, Storer B, Carpenter P, et al. Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14:1380-4.
36. Akpek G, Zahurak M, Piantadosi S, et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood. 2001;97:1219-26. (Pubitemid 32183742)
37. Vigorito A, Campregher P, Storer B, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood. 2009;114:702-8.